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Treatment of bone metastases from breast cancer with
(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)
R.E. Coleman, P.J. Woll, M. Miles, W. Scrivener & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London, SE] 9RT, UK.
Summary Twenty-eight patients with progressive symptomatic bone metastases from breast cancer received
(3-amino-l-hydroxypropylidene)-1,1-bisphosphonate (APD) 30mg in 500ml of 0.9% saline infused over 2h
every 14 days. No other systemic therapy for breast cancer was prescribed. All patients had progressed on at
least one previous systemic treatment. APD was continued until the disease progressed. Patients were assessed
for objective response by the UICC criteria. In addition, subjective response was determined by a pain
questionnaire.
Radiological evidence of bone healing with sclerosis of lytic disease (UICC partial response) was seen in
4 patients. The median duration of response was 10 months. Eleven patients had stable disease for at least 3
months (median 5 months) and 9 progressed. Symptomatic response occurred in 9 patients and 12 reported
an improvement in quality of life. Treatment was tolerated well with no significant toxicity.
In conclusion, long-term inhibition of bone destruction is possible with APD therapy alone and both
subjective and objective responses are seen.
Bone metastases are common in advanced breast cancer and
a major cause of morbidity. Pain especially, but also patho-
logical fracture, hypercalcaemia and bone marrow infilt-
ration, cause disability. Palliation is possible with
radiotherapy or systemic anticancer treatments and the clini-
cal course is often long (Coleman & Rubens, 1987a). How-
ever, progressive skeletal destruction leads to increasing
immobility, a deterioration in quality of life and premature
death.
Our understanding of the pathogenesis of skeletal metas-
tases is incomplete but activation of osteoclasts is clearly
relevant (Coleman & Rubens, 1985). Tumour cells secrete a
variety of paracrine factors which stimulate osteoclastic bone
resorption. Normal coupling between osteoclast and osteob-
last results in new bone formation although in metastatic
bone disease this may be disturbed. Typically in advanced
breast cancer resorption predominates and lytic bone metas-
tases develop (Galasko, 1976).
The diphosphonates (biphosphonates) are compounds con-
taining a P-C-P structure by which they bind tightly to
calcified bone matrix (Powell & Denmark, 1985). Some, in-
cluding (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate
(APD), are potent inhibitors of bone resorption. The mech-
anism of action is unclear but may involve direct biochemical
effects on the osteoclast (Boonekamp et al., 1986), prevention
of osteoclast attachment to the bone matrix (Fleisch, 1982)
or inhibition of osteoclast differentiation and recruitment
(Boonekamp et al., 1987). APD has been successfully used
in the control of a variety of benign conditions characterised
by increased bone resorption including Paget's disease
(Harinck et al., 1987), disuse and steroid-induced osteoporosis
(Hoekman et al., 1985; Reid et al., 1988; Huaux et al.,
1985). APD is highly effective also for the control of hyper-
calcaemia ofmalignancy (Sleeboom et al., 1983; Ralston et al.,
1985; Coleman & Rubens, 1987b) and a recent study has
shown that APD in combination with systemic anticancer
treatment reduces the morbidity caused by tumour-induced
osteolysis (van Holten-Verzanvoort et al., 1987).
We have studied the effects of APD on a group of patients
with progressive lytic bone metastases from breast cancer.
No other systemic anticancer treatment was prescribed
allowing a detailed assessment of objective, symptomatic and
biochemical response to APD.
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Patients and methods
Twenty-eight patients with progressive symptomatic bone
metastases from advanced breast cancer were studied. The
median age was 52 (range 32-73). All patients had confirma-
tion of progressive lytic, or mixed lytic and sclerotic, bone
metastases on serial radiographs. Skeletal disease was widely
disseminated throughout the axial skeleton in all patients.
Metastatic disease was confirmed to the bone in 23. In 5
patients stable asymptomatic extra-skeletal disease was
present affecting the skin (3 patients), pleura (2 patients)
and, in one patient each, breast, lymph nodes, lung and
brain.
All patients had received previous systemic treatment; 27
endocrine treatment, 12 chemotherapy and 11 both (Table I).
A four week withdrawal period was observed after additive
hormone treatment (e.g., progestogens) or chemotherapy.
Informed consent was obtained.
APD (Ciba-Geigy Pharmaceuticals Ltd., Horsham) was
given every 14 days at a dose of 30 mg by intravenous
infusion in 500ml of normal (0.9%) saline over 2h. Treat-
ment was continued until progression of disease. The median
number of APD treatments was eight (range 2-34). No other
systemic anticancer treatment was prescribed. Radiotherapy
Table I Previous treatments
No. treatments No. patients
Endocrine
Adjuvant 0 27
1 1
Advanced diseased 0 1
1 13
2 8
3 4
4 1
5 1
Chemotherapy
Adjuvant 0 24
1 4
Advanced disease 0 16
1 8
2 3
3 1
Radiotherapy to bone metastases
No 5
Yes 23
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to painful sites of disease and analgesics were given as
necessary.
Objective, symptomatic and biochemical response to treat-
ment were assessed. The UICC response criteria (Hayward et
al., 1977) were used to assess objective response. A partial
response was recorded when radiological evidence of sclero-
sis within previously lytic bone metastases was seen with no
evidence of new lesions. The response category 'no change'
indicated stabilisation of disease on plain radiographs for at
least 3 months. An increase in the size of one or more
baseline lesions or the appearance of new lesions was
recorded as progressive disease. Purely sclerotic lesions were
considered unassessable.
Two methods were used to assess symptomatic response:
(1) a questionnaire recording pain intensity, analgesic con-
sumption, mobility and performance status completed by the
patient at each visit. A 'pain score' was derived from this
information and expressed as a percentage of the maximum
possible score (Table II); (2) a single question to the patient
at 3 months (or sooner in the event of progressive disease)
inquiring of the overall effect of treatment on quality of life.
Markers of bone metabolism used to follow the biochemi-
cal response to treatment were serum calcium, alkaline
phosphatase and osteocalcin (BGP) and urinary calcium
excretion. Monthly serum measurements of calcium, creati-
nine, alkaline phosphatase and phosphate were performed on
a morning blood sample using a standard multi-channel
autoanalyser. Serum for osteocalcin measurements was
stored at -20°C and determined by radioimmunoassay
using the Immuno Nuclear Osteocalcin RIA kit (Price et al.,
1980). A spot sample of urine was collected after an
overnight fast and voiding of urine in the morning for
measurement of urinary calcium excretion (Nordin, 1976).
All samples were collected on the morning before treatment
with APD.
Results
Response of skeletal disease to treatment was assessable in
24 patients (Table III). In 4 patients assessment was not
possible because of either extra-skeletal progression (2
patients) or lack of follow-up data (2 patients). Radiographic
evidence of bone healing (Figures 1 & 2) was seen in 4/24
Table III Response data (n=28)
Objective bone response (UICC)
Partial response 4 (9, 9, 12, 18+ months)
Stable disease 11 (median 5 months, range 3-7 months)
Progressive disease 9
Not assessable 4 - extra-skeletal progression: 2
- lost to follow-up: 2
Subjective response
Improvement
No change
Deterioration
Not assessable
Global' Pain scoreb
12 9
6
8
2
11
4
4
aPatient assessment of overall subjective benefit from APD treat-
ment; bDerived as shown in Table H.
Table II Derivation of pain score from questionnaire
Parameter Description Score
Pain None 0
Mild
Moderate
Severe
Very severe
Intolerable
Analgesic use None
Simple analgesic or NSAID
Simple analgesic+NSAID
Moderate analgesic (e.g. DFI18)
Opiates (<40mg morphine daily)
Opiates (>40mg morphine daily)
Mobility
Performance
status
Normal
Vigorous exercise/activity impaired
Climbing stairs/walking/bending
impaired
Difficulty with dressing/washing
Difficulty with all activities
Totally dependent and bedbound
Normal
Light work possible
Up and about >50% of the day
Confined to bed >50% of the day
Completely bedbound
l
2
3
4
5
0
1
2
3
4
5
0
1
2
3
4
5
0
1
2
3
4
Symptom score expressed as a percentage of maximum total Figure 1 Plain radiographs of the left upper humerus (a) before
and (b) 6 months after treatment with APD. The lytic lesion has
undergone sclerosis.APD TREATMENT OF BONE METASTASES 623
this occasion the patient failed to respond. One patient
remains on APD, in remission and off all analgesics, at 18
months. Two responding patients subsequently developed
progressive disease outside the skeleton (liver 1 pt., skin lpt.)
necessitating a change of treatment. Restaging at this time
showed no evidence of progressive skeletal disease. Stabilisa-
tion of previously progressive bone disease for a minimum of
3 months (median 5 months, range 3-7 months) occurred in
11 patients (46%). Two had radiological evidence of sclerosis
but radiographs of other sites showed new lytic areas. In 6,
extraskeletal progression occurred, necessitating a change in
treatment, before any evidence of deteriorating skeletal dis-
ease. The median time to progressive bone disease was 16
weeks (range 5-78+ weeks) and occurred within 3 months in
8 patients (33%). The median duration of survival has not
been reached but is more than 38 weeks.
The mean pain score fell from 53% to 49% after 3
months' treatment. This change was not significant but 9
patients showed a > 10% improvement in symptom score. In
5 patients dramatic symptomatic improvement occurred
allowing a major increase in mobility. All of these patients
remain pain free more than a year later, 4 having disconti-
nued opiate analgesia. All patients with symptomatic impro-
vement had stabilisation of disease or bone healing on plain
radiographs. Twelve patients reported global improvement in
quality of life (Table III), 11 with stable or improving
radiological signs. Six patients reported a cyclical pattern to
their pain with improvement after treatment and an increase
in pain during the few days before the next dose of APD.
Morbidity resulting from bone metastases included patho-
logical fracture, cord compression, marrow infiltration and
hypercalcaemia and these events are summarised in Table
i v. 111ne pa4t1iets We1r niypelr4aicaenuc t tnel start ou
treatment. APD corrected the serum calcium to normal but
recurrence of hypercalcaemic refractory to further doses of
APD and progressive bone metastases developed in 2 within
3 months.
A transient but significant fall in serum calcium was seen
at 1 month (Table V). The fall in urinary calcium excretion
was more marked and persisted throughout treatment. A fall
in urinary calcium excretion was seen in 23/25 (92%)
patients with serial measurements. Despite inhibition of bone
resorption there was no suggestion of inhibition of osteoblast
activity. Levels of serum alkaline phosphatase activity and
osteocalcin increased, although not significantly, during
treatment.
APD was tolerated without serious toxicity. No gastro-
intestinal toxicity or alopecia was seen. Renal function as
determined by serum creatinine was unaffected. Slight eleva-
tion of liver transaminases (1-2 times normal upper limit)
occurred in 7 patients. This was of uncertrain significance
but in 3 patients was attributable to the development of liver
metastases. One patient had a mild pyrexia on the evening of
treatment (on 2 occasions). Two patients developed lympho-
penia (lymphocyte count <0.5 x1091-1) and another two
Figure 2 Plain radiographs of the left ilium (a) before and (b) 6
months after treatment with APD. The lytic areas in the ilium
have undergone sclerosis.
patients (17%), in whom sclerosis of lytic lesions occurred
with no evidence of new lesions. The sites undergoing
sclerosis were outside the fields of previous radiotherapy.
The median duration of response was 10 months (range 9-
18+). In one responding patient APD was stopped after 6
months' treatment and progression of disease was visible on
plain radiographs 3 months later. APD was resumed but on
Table IV Complications of metastatic bone involvement
Temporal relationship
to APD treatment
<I month <1 month
Morbidity before during after
Radiotherapy to
painful bone lesions 4 5 2
Pathological fracture
of long bone 0 1 2
Spinal cord compression 0 4a 0
Hypercalcaemia 3b 1 0
Leuco-erythroblastic anaemia 0 3 0
aThree at a site of progressive vertebral collapse and one due to
epidural extension of the tumour; bHypercalcaemia controlled by
APD but returned during treatment in two patients.
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Table V Effect of APD on biochemical markers of bone metabolism
Month
0 1 3
Serum calcium
(NR 2.1-2.6mmolP') 2.39 (0.04) 2.29a (0.04) 2.39 (0.12)
Serum alkaline phosphatase
(NR 80-300Iul-1) 507 (52) 652 (76) 562 (81)
Serum osteocalcin
(NR 1.8-4.6ngml-') 4.0 (0.53) 4.6 (0.69) 4.5 (0.63)
Urinary calcium/creatinine ratio
(<0.4mmolmol -1) 0.87 (0.13) 0.32b (0.06) 0.40b (0.09)
Values given are mean+s.e.m. Significantly different from month 0 value: ap<0.05,
bp<o.01; NR=normal range for our hospital.
hyperphosphataemia (serum phosphate > 1.5mmol1-1). Two
patients had grand mal convulsions; in one cerebral metas-
tases were detected on CT brain scan but in the other no
metabolic or structural cause could be found. No further fits
since stopping APD have occurred and to date, metastatic
disease has not developed in the central nervous system.
Discussion
In this study we have shown that APD, in the absence of
any other systemic treatment for breast cancer, is able to
halt the metastatic destruction of bone. Seventeen per cent
showed evidence of bone healing on plain radiographs and
46% stabilisation of disease. Accompanying this was a
reduction in pain score and increased mobility. Symptomatic
response was occasionally dramatic and osteolytic destruc-
tion inhibited for many months. Although not formally
tested there was an indication that APD improved quality of
life. Treatment was well tolerated.
Biochemical improvement has been noted in previous
studies of diphosphonates in metastatic bone disease (van
Holten-Verzantvoort et al., 1987; Elomaa et al., 1983; van
Breukelen et al., 1974; Siris et al., 1980), and a reduction in
morbidity reported in placebo-controlled studies (van
Holten-Verzantvoort et al., 1987; Elomaa et al., 1983).
Inhibition of new lesion formation has been noted in animal
(Jung et al., 1984) and human studies (Elomaa et al., 1985)
but none have reported radiological improvement in metas-
tatic bone disease.
The diphosphonates possess no cytotoxic or immuno-
suppressive activity (Garattini et al., 1987) and so the
structural improvement in bone lesions in some patients
needs alternative explanation. In metastatic bone disease
bone formation and resorption rates are typically increased
(Delmas et al., 1987; Coleman et al., 1988). Specific inhibi-
tion of bone resorption stops the efflux of calcium from the
skeleton while continuing osteoblast activity permits new
bone formation to occur (Parfitt, 1980). An acute increase in
the bone mass following treatment with APD has been seen
in normal rat bone (Reitsma et al., 1980), bone affected by
the mouse 5T2 multiple myeloma (Radl et al., 1985) and
patients with steroid-induced osteoporosis (Reid et al., 1988).
The optimum schedule and route of administration of
APD has not been defined. We have shown previously that a
single intravenous dose of 15-30mg of APD will control
hypercalcaemia secondary to advanced breast cancer for a
median of 11 days (Coleman & Rubens, 1987b). Multi-dose
and single dose intravenous infusions of APD appear to be
equally effective in the treatment of hypercalcaemia of
malignancy (Yates et al., 1987) and above a dose of
0.25mgkg-1 there does not appear to be a dose-response
relationship (Body et al., 1987). On the basis of these data
we selected the two-weekly schedule and dose of intravenous
APD used in this study.
Extra-skeletal progression was common and the reason for
changing treatment in 12 patients. This presumably reflects
the lack of specific anticancer treatment. Whether this had
any influence on the development of bone marrow infilt-
ration and spinal cord compression through intra-medullary
and epidural extension is speculative, but the incidence of
these complications was higher than we would have expected
(Coleman & Rubens, 1987a).
In conclusion, we have shown that APD is an effective
drug for inhibiting bone resorption secondary to advanced
breast cancer. The role of APD in conjunction with systemic
antitumour therapy for the treatment and prevention of bone
metastases is now being studied in a controlled randomised
trial.
We are grateful to Ciba-Geigy Ltd. for suplies of APD and their
generous support for this study. We wish to thank the nursing and
clinical staff involved in the care of patients reported in this study
and Linda Fletcher for secretarial assistance.
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